Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the ...
TipRanks on MSN

Atossa completes FDA meeting on regulatory strategies

Atossa Therapeutics ( ($ATOS) ) has shared an announcement. On December 4, 2025, Atossa Therapeutics announced the completion of a Type C meeting ...

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments ...
TipRanks on MSN

Atossa Therapeutics, Insilico Medicine publish study of (Z)-endoxifen in GBM

Atossa Therapeutics (ATOS) and Insilico Medicine, a company dealing in AI-powered drug discovery, announced the publication of a joint study ...
Seeking Alpha

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for ...
Nasdaq

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Changes are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans SEATTLE, Oct. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc.
Nasdaq

Atossa Therapeutics Receives U.S. Patent for (Z)-Endoxifen Oral Formulations to Enhance Breast Cancer Treatment Options

Atossa Therapeutics, Inc. announced the granting of a new patent (U.S. Patent No. 12,275,684) by the USPTO for its enteric oral formulations of (Z)-endoxifen, a potent Selective Estrogen Receptor ...
Seeking Alpha

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs "Janet's extensive ...
KTLA

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

SEATTLE, July 29, 2025 /PRNewswire/ --Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive written ...
CNN

Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study

SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 ...

Atossa Therapeutics Inc: Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings SEATTLE, Dec. 4, 2025 /PRNewswire/ -- Atossa Therapeutics ...